{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:38:08Z","timestamp":1792719488109,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Nanchong Applied Technology Research and Development Special Project","award":["24YFZJZC0049"],"award-info":[{"award-number":["24YFZJZC0049"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Updated antimicrobial susceptibility testing (AST) breakpoints require implementation in laboratory systems, but the timing of device updates across revisions has not been quantified. We measured publicly visible intervals from US Food and Drug Administration (FDA) breakpoint actions to clearances for established automated AST platforms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Drug-specific FDA breakpoint actions from January 1, 2017, through August 23, 2026, were linked to 510(k) decision summaries for MicroScan, VITEK 2\/VITEK 2 Compact, and BD Phoenix when the public record supported the drug, organism group, platform, and updated breakpoint relationship. Total lag was decomposed into breakpoint-to-receipt submission lag and receipt-to-decision FDA review interval.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-nine FDA notice rows yielded 22 eligible breakpoint events. Among 103 screened decision summaries, 13 clearances supported 18 links; 16 primary links involving 11 unique clearances and 10 events met prespecified criteria. Median total lag was 22.3\u2009months (interquartile range, 9.1-42.0; range, 0.1-59.7), median submission lag was 13.3\u2009months (interquartile range, 5.7-32.8), and the median review interval among unique clearances was 6.9\u2009months (interquartile range, 3.1-7.7). Three submissions were received before the corresponding breakpoint action. No qualifying public link was identified for 12 events, but this cannot establish outdated labeling because cleared change protocols may permit updates without another 510(k).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Public 510(k) records show heterogeneous breakpoint-to-clearance intervals, with a longer prereceipt than review component. A dated, machine-readable registry of breakpoint-related labeling changes would improve transparency, including for updates made without a new 510(k).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag112","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:28Z","timestamp":1792712548000},"source":"Crossref","is-referenced-by-count":0,"title":["Publicly visible regulatory timing from US Food and Drug Administration breakpoint updates to automated antimicrobial susceptibility test clearances: a longitudinal database study, 2017-2026"],"prefix":"10.1093","volume":"166","author":[{"given":"Zilin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Xichong County People\u2019s Hospital , Nanchong, Sichuan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"He","sequence":"additional","affiliation":[{"name":"North Sichuan Medical College Institute of Basic Medicine and Forensic Medicine, , Nanchong, Sichuan,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"2026102221020010400_aqag112-B1","doi-asserted-by":"publisher","first-page":"e00139-18","DOI":"10.1128\/JCM.00139-18","article-title":"Impact of 21st Century Cures Act on breakpoints and commercial antimicrobial susceptibility test systems: progress and pitfalls","volume":"56","author":"Humphries","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2026102221020010400_aqag112-B2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/cid\/ciy432","article-title":"Twenty-first Century Cures Act and antimicrobial susceptibility testing: clinical implications in the era of multidrug resistance","volume":"67","author":"Humphries","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026102221020010400_aqag112-B3","doi-asserted-by":"publisher","first-page":"e00203-19","DOI":"10.1128\/JCM.00203-19","article-title":"Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories","volume":"57","author":"Humphries","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2026102221020010400_aqag112-B4","doi-asserted-by":"publisher","first-page":"e01154-22","DOI":"10.1128\/jcm.01154-22","article-title":"Updating breakpoints in the United States: a summary from the ASM Clinical Microbiology Open 2022","volume":"61","author":"Patel","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026102221020010400_aqag112-B5","doi-asserted-by":"publisher","first-page":"ofac007","DOI":"10.1093\/ofid\/ofac007","article-title":"Raising the bar: improving antimicrobial resistance detection by clinical laboratories by ensuring use of current breakpoints","volume":"9","author":"Simner","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026102221020010400_aqag112-B6","doi-asserted-by":"publisher","first-page":"e01488-18","DOI":"10.1128\/JCM.01488-18","article-title":"Public health efforts can impact adoption of current susceptibility breakpoints, but closer attention from regulatory bodies is needed","volume":"57","author":"McKinnell","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2026102221020010400_aqag112-B7","doi-asserted-by":"publisher","first-page":"ofac421","DOI":"10.1093\/ofid\/ofac421","article-title":"It\u2019s not you, it\u2019s SOSA: a case study on breaking up with an FDA-cleared susceptibility testing system\u2019s oxacillin results for Staphylococcus spp. other than S. aureus and S. lugdunensis","volume":"9","author":"Yang","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026102221020010400_aqag112-B8","doi-asserted-by":"publisher","first-page":"e104338","DOI":"10.7759\/cureus.104338","article-title":"Impact of outdated Clinical and Laboratory Standards Institute (CLSI) breakpoint implementation on antimicrobial susceptibility interpretation: a retrospective analytical study","volume":"18","author":"Goyal","year":"2026","journal-title":"Cureus"},{"key":"2026102221020010400_aqag112-B9","doi-asserted-by":"publisher","first-page":"e01617-22","DOI":"10.1128\/jcm.01617-22","article-title":"Evaluation of piperacillin-tazobactam testing against Enterobacterales by the Phoenix, MicroScan, and Vitek2 tests using updated Clinical and Laboratory Standards Institute breakpoints","volume":"61","author":"Manuel","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2026102221020010400_aqag112-B10","doi-asserted-by":"publisher","first-page":"e00048-25","DOI":"10.1128\/jcm.00048-25","article-title":"Evaluation of MicroScan and VITEK 2 systems for susceptibility testing of Enterobacterales with updated breakpoints","volume":"63","author":"Richter","year":"2025","journal-title":"J Clin Microbiol"},{"key":"2026102221020010400_aqag112-B11","doi-asserted-by":"publisher","first-page":"e00437-18","DOI":"10.1128\/JCM.00437-18","article-title":"The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group","volume":"56","author":"Humphries","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2026102221020010400_aqag112-B12","volume-title":"Antimicrobial Susceptibility Test (AST) System Devices\u2014Updating Breakpoints in Device Labeling: Guidance for Industry and Food and Drug Administration Staff","author":"US Food and Drug Administration","year":"2023"},{"key":"2026102221020010400_aqag112-B13","volume-title":"FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria","author":"US Food and Drug Administration","year":"2026"},{"key":"2026102221020010400_aqag112-B14","volume-title":"Notices of Updates","author":"US Food and Drug Administration","year":"2026"},{"key":"2026102221020010400_aqag112-B15","author":"US Food and Drug Administration","year":"2020"},{"key":"2026102221020010400_aqag112-B16","volume-title":"Breakpoint Implementation Toolkit","author":"Clinical and Laboratory Standards Institute","year":"2026"},{"key":"2026102221020010400_aqag112-B17","volume-title":"510(k) Premarket Notification Database","author":"US Food and Drug Administration","year":"2026"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/4\/aqag112\/72373144\/aqag112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/166\/4\/aqag112\/72373144\/aqag112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:02:10Z","timestamp":1792717330000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag112\/8979836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag112","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"aqag112"}}